Covid-19 once again dominated headlines in 2021—but it wasn't the only news story reshaping health care. Here's what Advisory Board experts saw as the year's biggest stories, from controversial drug approvals to the ongoing, industry-shaking "nurse exodus."

Experts say the most popular Covid-19 rapid tests are just as sensitive to omicron as to other coronavirus variants—but Michael Mina, the chief science officer at eMed, suggested that omicron's biology may affect when in the course of an illness the virus is detectable.

Biogen on Monday announced a 50% price reduction for its Alzheimer's drug, Aduhelm—and since the potential cost of covering the drug was a factor in CMS' calculation of 2022 Medicare premiums, advocates are now calling for the agency to lower premiums.

Even amid a radical increase in omicron infections, data from Google searches and social media interactions shows that Americans are engaging much less with Covid-19 news than in prior waves. However, Ashish Jha argues that a "middle course between dismay and dismissal" is needed to combat omicron.

FDA on Monday approved the first injectable treatment for HIV prevention, in today's bite-sized hospital and health industry news from the District of Columbia, Maryland, and Tennessee.